Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A | P20648 | 14/20 | 0.54 |
| ▸ | ATP4B | P51164 | 14/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.54 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | FASN | P49327 | 1/20 | 0.54 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.54 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.54 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.54 |
| ▸ | ATP1A1 | P05023 | 7/20 | 0.45 |
| ▸ | ATP1B1 | P05026 | 7/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pantoprazole SCHEMBL6469440 | 1.00 | ATP4A (0.54) | ATP4AATP4BCYP2C9KDM4ESLC22A2 | |
| Pantoprazole SCHEMBL4942069 | 1.00 | ATP4A (0.54) | ATP4AATP4BCYP2C9KDM4ESLC22A2 | |
| Pantoprazole SCHEMBL29465 | 1.00 | ATP4A (0.54) | ATP4AATP4BCYP2C9KDM4ESLC22A2 | |
| Pantoprazole SCHEMBL29425016 | 1.00 | ATP4A (0.54) | ATP4AATP4BCYP2C9KDM4ESLC22A2 | |
| Pantoprazole SCHEMBL12662938 | 1.00 | ATP4A (0.54) | ATP4AATP4BCYP2C9KDM4ESLC22A2 | |
| Pantoprazole SCHEMBL1716777 | 0.99 | ATP4A (0.53) | ATP4AATP4BCYP2C9KDM4ESLC22A2 | |
| Pantoprazole SCHEMBL6262319 | 0.99 | ATP4A (0.53) | ATP4AATP4BCYP2C9KDM4ESLC22A2 | |
| Pantoprazole SCHEMBL4320242 | 0.99 | ATP4A (0.53) | ATP4AATP4BCYP2C9KDM4ESLC22A2 | |
| Pantoprazole SCHEMBL1994484 | 0.99 | ATP4A (0.53) | ATP4AATP4BCYP2C9KDM4ESLC22A2 | |
| Pantoprazole SCHEMBL3716300 | 0.99 | ATP4A (0.53) | ATP4AATP4BCYP2C9KDM4ESLC22A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11001866-B2 | Burkholderia and applications thereof | JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD. (CN) | 2021-05-11 | — | — | US | claimed |
| US-20200385770-A1 | BURKHOLDERIA AND APPLICATIONS THEREOF | JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD. (CN) | 2020-12-10 | — | — | US | claimed |
| US-20080234326-A1 | Novel Salts of Pantoprazole and (S) - Pantoprazole | ALTANA PHARMA AG (DE) | 2008-09-25 | — | — | US | claimed |
| EP-1711179-A2 | CALCIUM, POTASSIUM, ZINC, LITHIUM AND ALUMINIUM SALTS OF PANTOPRAZOLE AND (S)-PANTOPRAZOLE | Altana Pharma AG (DE) | 2006-10-18 | — | — | EP | claimed |
| US-20050288334-A1 | Process for preparing optically pure active compounds | ALTANA PHARMA AG (DE) | 2005-12-29 | — | — | US | claimed |
| EP-1578742-A1 | PROCESS FOR PREPARING OPTICALLY PURE ACTIVE COMPOUNDS | ALTANA Pharma AG (DE) | 2005-09-28 | — | — | EP | claimed |
| WO-2005074929-A2 | CALCIUM, POTASSIUM, ZINC, LITHIUM AND ALUMINIUM SALTS OF PANTOPRAZOLE AND (S)-PANTOPRAZOLE | ALTANA PHARMA AG (DE) | 2005-08-18 | — | — | WO | claimed |
| WO-2004052882-A1 | PROCESS FOR PREPARING OPTICALLY PURE ACTIVE COMPOUNDS | ALTANA PHARMA AG (DE) | 2004-06-24 | — | — | WO | claimed |
| US-20220202796-A1 | CXCL10 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-06-30 | — | — | US | disclosed |
| US-20210338650-A1 | CXCL10 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-11-04 | — | — | US | disclosed |
| US-11001866-B2 | Burkholderia and applications thereof | JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD. (CN) | 2021-05-11 | — | — | US | disclosed |
| US-11001866-B2 | Burkholderia and applications thereof | JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD. (CN) | 2021-05-11 | — | — | US | disclosed |
| EP-3380085-B1 | ORAL PREPARATIONS WITH OMEPRAZOLE OR PANTOPRAZOLE | SYMRISE AG (DE) | 2021-01-13 | — | — | EP | disclosed |
| US-20200385770-A1 | BURKHOLDERIA AND APPLICATIONS THEREOF | JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD. (CN) | 2020-12-10 | — | — | US | disclosed |
| US-20120197021-A1 | OPTICAL RESOLUTION OF SUBSTITUTED 2-(2-PYRIDINYLMETHYLSULPHINYL)-1H-BENZIMIDAZOLES | HETERO RESEARCH FOUNDATION (IN) | 2012-08-02 | — | — | US | disclosed |
| US-20120197021-A1 | OPTICAL RESOLUTION OF SUBSTITUTED 2-(2-PYRIDINYLMETHYLSULPHINYL)-1H-BENZIMIDAZOLES | HETERO RESEARCH FOUNDATION (IN) | 2012-08-02 | — | — | US | disclosed |
| WO-2011042910-A2 | OPTICAL RESOLUTION OF SUBSTITUTED 2-(2- PYRIDINYLMETHYLSULPHINYL)-1H-BENZIMIDAZOLES | HETERO RESEARCH FOUNDATION (IN) | 2011-04-14 | — | — | WO | disclosed |
| WO-2009147178-A2 | NOVEL MEDICAL USE OF SUBSTITUTED PYRIDIN-2-YLMETHYLSULPHINYL-1H-BENZIMIDAZOLES | NYCOMED GMBH (DE) | 2009-12-10 | — | — | WO | disclosed |
| EP-1711179-A2 | CALCIUM, POTASSIUM, ZINC, LITHIUM AND ALUMINIUM SALTS OF PANTOPRAZOLE AND (S)-PANTOPRAZOLE | Altana Pharma AG (DE) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005074929-A2 | CALCIUM, POTASSIUM, ZINC, LITHIUM AND ALUMINIUM SALTS OF PANTOPRAZOLE AND (S)-PANTOPRAZOLE | ALTANA PHARMA AG (DE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220202796-A1 | CXCL10 Inhibitors | CXCL10, CCL5, CCL11 | ATP4A 4581/4885ATP4B 4629/4885CYP2C9 4152/4885 |
| US-20120197021-A1 | OPTICAL RESOLUTION OF SUBSTITUTED 2-(2-PYRIDINYLMETHYLSULPHINYL)-1H-BENZIMIDAZOLES | BRI3BP, HRH2, BRPF1 | ATP4A 595/4885ATP4B 1246/4885CYP2C9 598/4885 |
| US-20210338650-A1 | CXCL10 Inhibitors | CXCL10, CCL5, CCL11 | ATP4A 4581/4885ATP4B 4629/4885CYP2C9 4152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.